BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
BioAge Labs, Inc.NASDAQ: BIOA
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 96.4% from a year ago
Net receivables stood at $709K at the end of Q1 FY2026, up 96.4% from a year earlier and down 7.8% from the prior quarter.
Context
- Net receivables amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +96.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 769K USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 769K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Net Receivables vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +96.4% is the 2nd highest of 6, against a peer median of +1.0%.
- Net receivables amounts to 0.2% of total assets for BIOA, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$44.69M CAD | +5.8% | +2.6% | 7.4% | |
| Mar 2026 | CA$36.29M CAD | -31.2% | -19.1% | 3.2% | |
| Dec 2025 | $33.82M USD | — | — | 14.6% | |
| Mar 2026 | $5.67M USD | +1.0% | +2.5% | 5.7% | |
| Mar 2026 | $2.59M USD | +408.2% | +43.4% | 1.7% | |
| Mar 2026 | $1.3M USD | — | — | 0.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | $709K USD | +96.4% | — | 0.2% |
| Mar 2026 | $434K USD | -11.1% | +142.3% | 0.4% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | +1.0% | +2.6% | 1.7% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.